

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

RRID:AB_10544692

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4322, RRID:AB_10544692

Antibody Information

URL: http://antibodyregistry.org/AB_10544692

Proper Citation: Cell Signaling Technology Cat# 4322, RRID:AB_10544692

Target Antigen: Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F. Consolidation on 10/2018: AB_10544692, AB_10548756.

Antibody Name: Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

Description: This monoclonal targets Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

Target Organism: b, rat, h, m, mouse, r, bovine, human, mk

Antibody ID: AB_10544692

Vendor: Cell Signaling Technology

Catalog Number: 4322

Record Creation Time: 20250820T063020+0000

Record Last Update: 20250821T001755+0000

Ratings and Alerts

- Used for western blot assay by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang K, et al. (2024) VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell reports, 43(1), 113661.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. Cell reports. Medicine, 5(7), 101645.

Xu H, et al. (2024) Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity. Immunity, 57(8), 1796.

Miao N, et al. (2024) Tumor cell-intrinsic Piezo2 drives radioresistance by impairing CD8+ T cell stemness maintenance. The Journal of experimental medicine, 221(10).

Kang CW, et al. (2024) Excess endocrine growth hormone in acromegaly promotes the aggressiveness and metastasis of triple-negative breast cancer. iScience, 27(7), 110137.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell reports. Medicine, 5(5), 101526.

Zhang C, et al. (2024) Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression. Developmental cell, 59(23), 3072.

Balcioglu O, et al. (2024) Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation. NPJ breast cancer, 10(1), 80.

Maharaj AV, et al. (2024) QSOX2 Deficiency-induced short stature, gastrointestinal dysmotility and immune dysfunction. Nature communications, 15(1), 8420.

H??gild ML, et al. (2023) Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance. The Journal of clinical endocrinology and metabolism, 108(3), 653.

Lin C, et al. (2023) S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. Cancer research communications, 3(3), 420.

Liu C, et al. (2023) Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma. *iScience*, 26(8), 107369.

Arwood ML, et al. (2023) New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. *Cell chemical biology*, 30(6), 618.

Andrews A, et al. (2023) Characterization of dominant-negative growth hormone receptor variants reveals a potential therapeutic target for short stature. *European journal of endocrinology*, 188(4), 353.

Chhabra Y, et al. (2023) Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation. *Cell reports*, 42(5), 112490.

Li Y, et al. (2023) N6-methyl-2'-deoxyadenosine promotes self-renewal of BFU-E progenitor in erythropoiesis. *iScience*, 26(6), 106924.

Huang H, et al. (2023) Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins. *Blood science (Baltimore, Md.)*, 5(4), 258.

Sun SL, et al. (2023) Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 169, 115905.

Efthymiou V, et al. (2023) Inhibition of AXL receptor tyrosine kinase enhances brown adipose tissue functionality in mice. *Nature communications*, 14(1), 4162.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer discovery*, 12(3), 752.